SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 398,364.39 |
Enterprise Value ($M) | 423,896.39 |
Book Value ($M) | 74,599.00 |
Book Value / Share | 28.54 |
Price / Book | 5.34 |
NCAV ($M) | -55,280.00 |
NCAV / Share | -21.15 |
Price / NCAV | -7.21 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.16 |
Return on Assets (ROA) | 0.10 |
Return on Equity (ROE) | 0.26 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.77 |
Current Ratio | 0.99 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 55,294.00 |
Assets | 187,378.00 |
Liabilities | 110,574.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 94,943.00 |
Operating Income | 25,673.00 |
Net Income | 17,941.00 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 21,194.00 |
Cash from Investing | -12,371.00 |
Cash from Financing | -8,871.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | State Street Corp | 5.45 | -1.76 | |
13G/A | Vanguard Group Inc | 9.44 | 5.13 | |
13G/A | BlackRock Inc. | 7.60 | -0.61 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
1,129,586 | 8,919,373 | 12.66 | |
520,580 | 5,596,404 | 9.30 | |
447,674 | 5,132,769 | 8.72 | |
584,632 | 5,420,836 | 10.78 | |
(click for more detail) |